Hepatic Osteodystrophy: A Global (Re)View of the Problem.

Area of Science:

• Hepatology
• Endocrinology
• Bone Metabolism

Background:

• Hepatic osteodystrophy (low bone mineral density) is a frequent complication of chronic liver diseases.
• It often goes undiagnosed and untreated, leading to osteoporosis or osteopenia.
• This condition significantly impacts patient quality of life.

Purpose of the Study:

• To review the prevalence, pathophysiology, diagnosis, and management of hepatic osteodystrophy.
• To consolidate current knowledge on bone density loss in chronic liver disease.
• To highlight the need for better treatment strategies.

Main Methods:

• A narrative review of existing medical literature.
• Searches conducted across PubMed, Google Scholar, Wiley, Science Direct, and Springer Link.
• Inclusion of studies on low bone mineral density linked to chronic liver diseases.

Main Results:

• Increased prevalence of osteoporosis/osteopenia reported in chronic liver disease patients.
• Multifactorial pathogenesis identified, including genetic, nutritional, hormonal, and medication-related factors.
• Vitamin D, calcium, and bisphosphonates recommended for management.

Conclusions:

• Hepatic osteodystrophy requires individualized fracture risk assessment and bone density evaluation.
• Supplementation and bisphosphonates are key components of current management.
• Further research is needed to optimize treatment and prevent fragility fractures, improving patient outcomes.